Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 04 2021
Historique:
received: 19 08 2020
revised: 22 12 2020
accepted: 01 02 2021
pubmed: 7 2 2021
medline: 12 8 2021
entrez: 6 2 2021
Statut: ppublish

Résumé

Gastric cancer is the third most lethal cancer worldwide, and evaluation of the genomic status of gastric cancer cells has not translated into effective prognostic or therapeutic strategies. We therefore hypothesize that outcomes may depend on the tumor microenvironment (TME), in particular, cancer-associated fibroblasts (CAF). However, very little is known about the role of CAFs in gastric cancer. To address this, we mapped the transcriptional landscape of human gastric cancer stroma by microdissection and RNA sequencing of CAFs from patients with gastric cancer. A stromal gene signature was associated with poor disease outcome, and the transcription factor heat shock factor 1 (HSF1) regulated the signature. HSF1 upregulated inhibin subunit beta A and thrombospondin 2, which were secreted in CAF-derived extracellular vesicles to the TME to promote cancer. Together, our work provides the first transcriptional map of human gastric cancer stroma and highlights HSF1 and its transcriptional targets as potential diagnostic and therapeutic targets in the genomically stable tumor microenvironment. SIGNIFICANCE: This study shows how HSF1 regulates a stromal transcriptional program associated with aggressive gastric cancer and identifies multiple proteins within this program as candidates for therapeutic intervention. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/7/1639/F1.large.jpg.

Identifiants

pubmed: 33547159
pii: 0008-5472.CAN-20-2756
doi: 10.1158/0008-5472.CAN-20-2756
pmc: PMC8337092
mid: NIHMS1672347
doi:

Substances chimiques

HSF1 protein, human 0
Heat Shock Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1639-1653

Subventions

Organisme : NIDDK NIH HHS
ID : P01 DK062041
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA118875
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034933
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA087837
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

N Engl J Med. 2001 Sep 13;345(11):784-9
pubmed: 11556297
PLoS One. 2016 Aug 11;11(8):e0161007
pubmed: 27513329
Autophagy. 2020 May;16(5):782-796
pubmed: 31286822
Oncotarget. 2017 Aug 9;8(41):70271-70280
pubmed: 29050278
Nat Cancer. 2020 Jul;1(7):692-708
pubmed: 35122040
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Nat Commun. 2019 Jan 10;10(1):130
pubmed: 30631061
FASEB J. 2015 Jan;29(1):274-85
pubmed: 25359493
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Cancer Res. 2019 Nov 15;79(22):5884-5896
pubmed: 31585941
Sci Rep. 2016 Sep 16;6:33366
pubmed: 27632935
J Biol Chem. 1998 Mar 27;273(13):7523-8
pubmed: 9516453
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Oral Oncol. 2011 Sep;47(9):840-6
pubmed: 21727023
Gastroenterology. 2011 Aug;141(2):476-85, 485.e1-11
pubmed: 21684283
Cell. 2012 Aug 3;150(3):549-62
pubmed: 22863008
Surg Oncol. 2000 Jul;9(1):5-11
pubmed: 11525306
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Ther Adv Med Oncol. 2013 Mar;5(2):143-51
pubmed: 23450234
Mol Cancer. 2020 Feb 27;19(1):43
pubmed: 32106859
Nat Commun. 2018 May 3;9(1):1777
pubmed: 29725014
Diagn Pathol. 2018 Oct 17;13(1):80
pubmed: 30326922
J Exp Clin Cancer Res. 2010 Jun 08;29:66
pubmed: 20529313
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Int J Mol Sci. 2019 Nov 19;20(22):
pubmed: 31752429
Cancer Cell. 2010 Feb 17;17(2):135-47
pubmed: 20138012
J Exp Clin Cancer Res. 2018 Jul 9;37(1):143
pubmed: 29986759
Genome Biol. 2014;15(12):550
pubmed: 25516281
Anticancer Res. 2017 Jul;37(7):3547-3552
pubmed: 28668845
Front Mol Neurosci. 2016 May 10;9:32
pubmed: 27242425
Oncogene. 2019 Mar;38(11):1951-1965
pubmed: 30390075
Anticancer Res. 2018 May;38(5):2717-2722
pubmed: 29715091
Biomed Rep. 2015 Mar;3(2):207-214
pubmed: 26075074
Oncology. 2005;69 Suppl 1:17-22
pubmed: 16210872
BMC Med Genomics. 2010 Nov 03;3:51
pubmed: 21047417
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1886-94
pubmed: 17569883
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
Int J Oncol. 2017 May;50(5):1501-1512
pubmed: 28339036
JCI Insight. 2020 May 7;5(9):
pubmed: 32229725
Sci Rep. 2016 Mar 02;6:22519
pubmed: 26931825
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Mol Cancer. 2013 Dec 20;12(1):168
pubmed: 24354864
Oncotarget. 2017 Dec 1;8(67):112103-112115
pubmed: 29340115
Cell. 2014 Jul 31;158(3):564-78
pubmed: 25083868
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Cold Spring Harb Perspect Biol. 2016 Jul 01;8(7):
pubmed: 27328872
Cancer Lett. 2019 Feb 1;442:287-298
pubmed: 30439539
Science. 2014 Feb 14;343(6172):776-9
pubmed: 24531970
Gastroenterol Rep (Oxf). 2019 Feb;7(1):57-66
pubmed: 30792867
Hum Mol Genet. 1999 Apr;8(4):607-10
pubmed: 10072428
Cancer Treat Rev. 2014 Jul;40(6):692-700
pubmed: 24656602
Oncotarget. 2016 Mar 1;7(9):10255-70
pubmed: 26859571
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Oncogene. 2020 Apr;39(17):3427-3442
pubmed: 32123313
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Int J Cancer. 1996 Nov 27;68(5):571-6
pubmed: 8938136
Nat Rev Cancer. 2015 Aug;15(8):473-83
pubmed: 26156638
Nat Commun. 2020 Dec 7;11(1):6245
pubmed: 33288768
Sci Rep. 2019 Mar 15;9(1):4633
pubmed: 30874607

Auteurs

Nil Grunberg (N)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Meirav Pevsner-Fischer (M)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Tal Goshen-Lago (T)

Division of Oncology, Rambam Health Care Campus, Haifa, Israel.

Judith Diment (J)

Department of Pathology, Kaplan Medical Center, Rehovot, Israel.

Yaniv Stein (Y)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Hagar Lavon (H)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Shimrit Mayer (S)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Oshrat Levi-Galibov (O)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Gil Friedman (G)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Yifat Ofir-Birin (Y)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Li-Jyun Syu (LJ)

Department of Dermatology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

Cristina Migliore (C)

University of Torino, Department of Oncology, Candiolo; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.

Eyal Shimoni (E)

Department of Chemical Research Support, The Weizmann Institute of Science, Rehovot, Israel.

Salomon M Stemmer (SM)

Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.

Baruch Brenner (B)

Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.

Andrzej A Dlugosz (AA)

Department of Dermatology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Department of Cell & Developmental Biology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

David Lyden (D)

Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, New York.

Neta Regev-Rudzki (N)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel.

Irit Ben-Aharon (I)

Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Ruth Scherz-Shouval (R)

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel. ruth.shouval@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH